Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.043
AS - Asia 9.323
EU - Europa 5.415
SA - Sud America 1.503
AF - Africa 238
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 27.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.713
SG - Singapore 3.492
VN - Vietnam 1.707
HK - Hong Kong 1.414
CN - Cina 1.367
BR - Brasile 1.103
IT - Italia 1.084
RU - Federazione Russa 1.016
SE - Svezia 658
DE - Germania 609
IE - Irlanda 575
FR - Francia 316
GB - Regno Unito 275
IN - India 253
UA - Ucraina 183
CA - Canada 170
FI - Finlandia 158
ID - Indonesia 152
AR - Argentina 138
BD - Bangladesh 138
AT - Austria 137
MX - Messico 108
TR - Turchia 106
KR - Corea 104
IQ - Iraq 94
NL - Olanda 86
ZA - Sudafrica 77
JP - Giappone 69
EC - Ecuador 68
PK - Pakistan 67
PH - Filippine 61
ES - Italia 54
SA - Arabia Saudita 54
CO - Colombia 53
PL - Polonia 51
RO - Romania 49
VE - Venezuela 42
UZ - Uzbekistan 39
MA - Marocco 36
DK - Danimarca 30
CL - Cile 26
PY - Paraguay 25
KE - Kenya 23
CZ - Repubblica Ceca 22
JO - Giordania 20
MY - Malesia 20
TN - Tunisia 20
BE - Belgio 19
ET - Etiopia 19
UY - Uruguay 18
AL - Albania 17
LT - Lituania 17
PE - Perù 17
KZ - Kazakistan 16
AE - Emirati Arabi Uniti 15
IR - Iran 15
NP - Nepal 14
DZ - Algeria 13
JM - Giamaica 13
CH - Svizzera 12
EG - Egitto 12
OM - Oman 12
TH - Thailandia 11
PA - Panama 10
BO - Bolivia 9
IL - Israele 9
LB - Libano 9
AU - Australia 8
BH - Bahrain 8
HN - Honduras 8
PS - Palestinian Territory 8
AZ - Azerbaigian 7
GE - Georgia 7
MD - Moldavia 7
CR - Costa Rica 6
PT - Portogallo 6
SN - Senegal 6
TW - Taiwan 6
GR - Grecia 5
LY - Libia 5
NG - Nigeria 5
SY - Repubblica araba siriana 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
KG - Kirghizistan 4
LV - Lettonia 4
AM - Armenia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
GT - Guatemala 3
GY - Guiana 3
HU - Ungheria 3
AO - Angola 2
BT - Bhutan 2
BW - Botswana 2
CD - Congo 2
EU - Europa 2
HR - Croazia 2
KH - Cambogia 2
Totale 27.488
Salva come PNG Salva come JPEG
Città #
Singapore 2.003
Hong Kong 1.385
Ann Arbor 987
Ashburn 925
San Jose 822
Fairfield 590
Dublin 558
Woodbridge 491
Ho Chi Minh City 487
Chandler 466
Dallas 449
Houston 428
Hanoi 418
Frankfurt am Main 375
New York 370
Chicago 295
Los Angeles 295
Wilmington 290
Santa Clara 286
Milan 259
Princeton 230
Hefei 227
Seattle 223
Beijing 196
Cambridge 196
Jacksonville 196
The Dalles 190
Lauterbourg 136
Dearborn 130
Moscow 121
Jakarta 113
Altamura 111
Lawrence 111
Buffalo 102
Seoul 92
Paris 91
Vienna 88
Council Bluffs 83
São Paulo 81
Shanghai 77
Helsinki 75
San Diego 65
Da Nang 63
Haiphong 61
Tokyo 61
Nuremberg 56
London 53
Nanjing 53
Munich 50
Rome 50
Dong Ket 44
Warsaw 44
Galati 43
Montreal 43
Johannesburg 41
Orem 41
Baghdad 39
Biên Hòa 37
Lachine 37
Tashkent 37
Hải Dương 35
Boardman 32
Lappeenranta 32
Rio de Janeiro 31
Andover 30
Guangzhou 30
Toronto 30
Brooklyn 29
Chennai 29
Denver 29
Salt Lake City 29
Amsterdam 28
Kent 27
Phoenix 26
Pune 26
Quận Bình Thạnh 26
Brasília 25
Mexico City 25
Poplar 25
Quito 25
Stockholm 25
Ha Long 24
Belo Horizonte 23
Palermo 23
Thái Nguyên 23
Atlanta 22
Curitiba 22
Jeddah 22
Vũng Tàu 22
Addis Ababa 18
Bogotá 18
Brussels 18
Can Tho 18
Fremont 18
Manchester 18
Nairobi 18
Ninh Bình 18
Ottawa 18
Boston 17
Busto Arsizio 17
Totale 16.937
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 405
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 388
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 386
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 319
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 317
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 316
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 316
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 308
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 305
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 304
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 303
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 299
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 298
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 296
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 293
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 290
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 281
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 279
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 269
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 267
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 263
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 255
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 253
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 253
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 245
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 243
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 241
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 239
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 238
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 238
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 236
Unmasking tuberculosis in the era of antiretroviral treatment 235
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 232
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 228
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 226
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 224
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 223
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 221
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 215
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 214
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 213
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 212
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 210
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 208
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 205
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 205
Beware of biases in observational studies on anti-spike monoclonal antibodies 202
Knowledge, Use, and Misuse of Self-Prescribed Doxycycline Postexposure Prophylaxis in a Community-Based Preexposure Prophylaxis Service 200
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 199
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 199
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 197
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 196
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 195
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 193
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 193
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 193
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 192
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 189
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 186
To the editor 185
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 184
COVID-19 Infection among Incarcerated Individuals and Prison Staff in Lombardy, Italy, March 2020 to February 2021 183
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 183
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 182
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 181
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 177
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 176
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 175
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 175
Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition 173
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 172
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 171
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration 169
Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori 168
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 167
Associations between immune depression and cardiovascular events in HIV infection 166
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 165
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 165
Imported ciprofloxacin-resistant Neisseria meningitidis 164
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 161
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 155
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 155
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 154
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 153
Predictors of AIDS-defining events among advanced naïve patients after HAART 153
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 152
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 152
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry 150
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study 149
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 146
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 145
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 145
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 144
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 144
Compassionate Use of Remdesivir in Children With Severe COVID-19 144
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 144
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 142
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 141
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 140
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 139
Totale 21.337
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021238 0 0 0 0 0 0 0 0 0 0 81 157
2021/20221.481 68 88 368 136 63 111 31 113 58 72 125 248
2022/20232.134 264 585 198 156 141 377 19 114 178 28 50 24
2023/20241.798 62 52 87 47 216 459 356 67 181 54 33 184
2024/20256.379 279 718 595 216 430 244 376 151 458 798 600 1.514
2025/202612.035 1.490 964 1.186 1.321 1.417 716 2.006 611 906 1.180 238 0
Totale 28.292